Overview

Expanded Access Protocol Thymus Transplantation

Status:
Available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose is to provide access for patients who have immunodeficiency or severe autoimmune disease related to poor thymic function to cultured thymus tissue for implantation. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Eligible participants receive cultured thymus tissue for implantation and may undergo biopsy. Immune suppression may be given depending on the immune status and clinical condition of the participant. Immune function testing is continued for one year post-implantation.
Details
Lead Sponsor:
M. Louise Markert
Collaborator:
Enzyvant Therapeutics GmbH
Treatments:
Antilymphocyte Serum
Cyclosporine
Cyclosporins
Tacrolimus
Thymoglobulin